# The Rise, Fall, and Rise Again of Proton Therapy or

### **Never count out a well-financed therapy**

Anthony Zietman MD

Shipley Professor of Radiation Oncology

Massachusetts General Hospital

Harvard Medical School

# The rollercoaster ride of proton therapy and prostate cancer

- Hope
- Disappointment
- Shame
- Resurrection


# The rollercoaster ride of proton therapy and prostate cancer

- Hope
- Disappointment
- Shame
- Resurrection






### A century of "delivery tools" in radiation oncology




## The "arrow of progress"




Normal tissue sparing

#### **Protons – "The Point of the Arrow"**

# Protons – a substantial upgrade



# But let's discuss prostate cancer




# The rollercoaster ride of proton therapy and prostate cancer


- Hope
- Disappointment
- Shame
- Resurrection






### Physical uncertainties – the penumbra





# Physical uncertainties: Inhomogeneity and end-range-uncertainty




### **Biological uncertainties**

#### The RBE of a proton beam is approximated at 1.1


#### But.....


- It changes with LET
- It changes across the SOBP



- It is highest just beyond the Bragg peak
- It changes with fraction size
- It changes with A/B ratio of tissue

## **Biological uncertainties**






Foe and Friend

### Whole body radiation dose


# Prostate plan




Trofimov et al IJROBP 2007

## If comparing treatment plans......

LDR




**HDR** 



**Brachytherapy always wins!!** 


## Does it cure patients?

#### **University of Florida**



# Does it cure more patients than brachytherapy?

Case-matched analysis: n = 141 + 141



Coen et al IJROBP 2011

#### Can we dose-escalate further?

MGH-LLUMC prospective protocol 82Gy Passively scattered opposed lateral beams Median follow-up 32 months

	Late morbidity		
	GU	GI	
Grade 2+	30%	12%	
Grade 3+	8%	1%	

### Does it reduce morbidity?

#### Two contemporaneous cohorts:

• PROG 9509 9.4 years


Boston survey 5.9 years

	PROG 9509	Boston survey
Number	280	97
Age at survey	76	75
Urinary obst/irr	24.0	21.8
Incontinence	10.2	11.2
Bowel problems	7.8	10.6
Sexual problems	67.1	76.3

Talcott et JAMA 2010

### Does it reduce morbidity?

U Florida1285 patients with median FU 3.5 years



# Does it increase morbidity?

IMRT vs Protons HR

GI diagnoses 0.66


Hip fractures NS

ED NS

**Urinary incontinence:** NS

(diagnoses, and procedures)

# Physics looks better but could the biology be worse?



# Proton beam appears to be a reasonable treatment for prostate cancer...

....as are radical prostatectomy, IMRT, VMAT, brachytherapy, SBRT, and active surveillance.

# The rollercoaster ride of proton therapy and prostate cancer

- Hope
- Disappointment
- Shame
- Resurrection



# Prostate cancer was the economic driver for for the "Great Proton Expansion"

- PSA screening and a huge "need"
- Good results relative to 1990s alternatives
- Patient and industry advocacy
- The Internet
- Competition and the need for prestige projects
- Novel financing and minimal FDA scrutiny

### **Powerful influences**




# Societies that allow medical advertising regularly see "arms races"







# 65 UK Radical Prostatectomy centers 2010-2014 during an era of patient choice



Green – robotic centers Red – centers that closed Blue – non-robotic centers

### **Competition and the Prestige Project**

#### Patients and hospital CEOs alike want:

- Robotic surgery
- PET scanners
- Proton therapy centers

### **Competition and the Prestige Project**

How is a prestige project funded?

- Federal or state grants
- Deep pockets
- Philanthropy
- Loans

# Proton facility economics: the importance of prostate treatment

 "Simple" prostate treatments have 70% of reimbursement of "complex" (pediatric, skull base)

 But 3-5 prostate cases can be treated for every "complex": case

Johnstone et al JACR 2012

# Market forces can overwhelm a weak evidence base


Patterns of "care" become disconnected from evidence

E D I T O R I A L

# The *Titanic* and the Iceberg: Prostate Proton Therapy and Health Care Economics

Anthony L. Zietman, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA

## Problem identified at highest level



Ezekiel Emanuel – New York Times Dec 2011

"The practice of no value medicine"

## **Payers revolt**





# BlueCross BlueShield

## **Bottom drops out of the prostate "market"**

- Rise of active surveillance
- Rise of the robot







# IU Proton Therapy Center And Cyclotron **Facilities To Close**

By CASEY KUHN


Posted August 22, 2014



**f** Like 67 people like this. Sign Up to see what your friends like.

The IU Health Proton Therapy Center and Cyclotron facilities will close in January 2015.

#### Proton therapy center files for bankruptcy



Scripps Proton Therapy Center opened in 2014 with five treatment bays and a 90-ton cyclotron that used magnets to accelerate

# THE WALL STREET JOURNAL.

# Big Bets on Proton Therapy Face Uncertain Future

Insurers balk at expensive radiation treatment; can smaller machines turn the tide?

#### **Proton Therapy – At the "Tipping Point"**

- Payers revolt
- Lack of evidence base
- Alternative therapies
- Size and cost

Can anything stop the bubble bursting?

# The rollercoaster ride of proton therapy and prostate cancer

- Hope
- Disappointment
- Shame
- Resurrection

#### Can anything stop the bubble bursting?


- Rapid development of evidence
- Advances: IMPT, miniaturization, cost reduction
- New use model
- New payment model

#### Can anything stop the bubble bursting?

#### **Rapid development of evidence:**

- Multiple sites
- Collaborative grants and groups
- National trials of comparative effectiveness


Particle Therapy submissions to the Red Journal in the weeks preceding and following the deadline for the Special Edition








Low-Intermediate Risk Prostate Cancer




Pls Jason Efstathiou and Justin Bekelman Current accrual 270 patients – completes 2019


#### "Spot scanned" beams – the new wave

The dynamic application of scanned and modulated proton pencil beams



#### Planning with intensity modulation






#### Can anything stop the bubble bursting?

#### "Miniaturization":

- Single gantry systems
- Gantry-less machines
- More efficient proton production






#### Can anything stop the bubble bursting?

New use model

**Consortia: Michigan and NYC** 

New payment model

Payment on protocols
Reference pricing



# **Protons in the age of Hypofractionation**

Study	"Longer" Arm	"Shorter" Arm	Efficacy at 5 years	Late Toxicity	PROs
СННіР	37fx/2.0Gy	20fx/3.0Gy	Similar	Similar	Similar
PROFIT	39fx/2.0Gy	20fx/3.0Gy	Similar	Similar	Similar
NRG 0415	41fx/1.8Gy	28fx/2.5Gy	Similar	Small个 GU/GI	Reporting tomorrow
HYPRO	39fx/2.0 Gy	19fx/ <u>3.4Gy</u>	Similar	个GU	Not reported

#### **Proton beam therapy – US treatment centers**

2004



#### **Proton beam therapy – US treatment centers**

UT CO

2017

#### **Proton beam therapy – UK treatment centers**



#### **Government Commission:**

1 multi-gantry facility per 30m population Specific indications (no prostate) Research mandate

#### **Proton beam therapy – UK treatment centers**



#### **Private centers:**

- Risk generating unquenchable demand
- Risk undermining evidence-based indications

#### **Proton beam therapy – Holland**



4 facilities for 13 million people
Consortia
Decisions based upon comparative planning

#### **Proton beam therapy – Norway**



4 facilities for 5 million people Everyone will get protons for everything

Protons are here and will not go away

- Protons are here and will not go away
- Profit motive less but prestige motive high

- Protons are here and will not go away
- Profit motive less but prestige motive high
- Proton delivery will improve

- Protons are here and will not go away
- Profit motive less but prestige motive high
- Proton delivery will improve
- Proton biology will be worked out

- Protons are here and will not go away
- Profit motive less but prestige motive high
- Proton delivery will improve
- Proton biology will be worked out
- Proton delivery will become less expensive

- Protons are here and will not go away
- Profit motive less but prestige motive high
- Proton delivery will improve
- Proton biology will be worked out
- Proton delivery will become less expensive
- Proton delivery will be more evidence based

- Protons are here and will not go away
- Profit motive less but prestige motive high
- Proton delivery will improve
- Proton biology will be worked out
- Proton delivery will become less expensive
- Proton delivery will be more evidence based
- Protons will compete in the prostate "market" whether there in evidence or not

